Vysioneer
Unlocking lesion-level insights to make oncology trials smaller and faster
Problem
Tumor heterogeneity
60% of cancer patients develop a mixture of shrinking, stable, and growing tumors. Tumor heterogeneity poses a significant obstacle to personalized cancer medicine and impedes our understanding of long-term treatment outcomes.
Every tumor matters to cure cancer
Our Approach
AI-powered treatment efficacy assessment
Incorporating all lesions to confirm treatment outcomes sooner with smaller sample sizes
AI Automation
Extract all-lesion features beyond current response evaluation criteria
AI Prediction
Explore all-lesion biomarkers that predict treatment outcome
